Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1949 1
1953 1
1967 1
1968 1
1971 1
1979 1
1980 1
1981 1
1983 1
1984 4
1985 5
1988 2
1990 2
1991 4
1992 3
1993 3
1994 2
1995 2
1996 2
1997 2
1998 1
1999 1
2000 3
2001 4
2002 6
2003 12
2004 7
2005 9
2006 9
2007 5
2008 6
2009 5
2010 8
2011 5
2012 8
2013 6
2014 10
2015 11
2016 12
2017 11
2018 9
2019 6
2020 9
2021 12
2022 6
2023 8
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin in Patients with Chronic Kidney Disease.
The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. The EMPA-KIDNEY Collaborative Group, et al. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. N Engl J Med. 2023. PMID: 36331190 Free PMC article. Clinical Trial.
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.
Van Mieghem NM, Unverdorben M, Hengstenberg C, Möllmann H, Mehran R, López-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodés-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD; ENVISAGE-TAVI AF Investigators. Van Mieghem NM, et al. N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449183 Clinical Trial.
Gut Microbiota-Derived Short-Chain Fatty Acids Promote Prostate Cancer Growth via IGF1 Signaling.
Matsushita M, Fujita K, Hayashi T, Kayama H, Motooka D, Hase H, Jingushi K, Yamamichi G, Yumiba S, Tomiyama E, Koh Y, Hayashi Y, Nakano K, Wang C, Ishizuya Y, Kato T, Hatano K, Kawashima A, Ujike T, Uemura M, Imamura R, Rodriguez Pena MDC, Gordetsky JB, Netto GJ, Tsujikawa K, Nakamura S, Takeda K, Nonomura N. Matsushita M, et al. Among authors: hase h. Cancer Res. 2021 Aug 1;81(15):4014-4026. doi: 10.1158/0008-5472.CAN-20-4090. Epub 2021 May 26. Cancer Res. 2021. PMID: 34039634
Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T. Nangaku M, et al. Among authors: hase h. Nephrol Dial Transplant. 2023 May 4;38(5):1204-1216. doi: 10.1093/ndt/gfac242. Nephrol Dial Transplant. 2023. PMID: 36002026 Free PMC article. Clinical Trial.
High-fat diet promotes prostate cancer growth through histamine signaling.
Matsushita M, Fujita K, Hatano K, Hayashi T, Kayama H, Motooka D, Hase H, Yamamoto A, Uemura T, Yamamichi G, Tomiyama E, Koh Y, Kato T, Kawashima A, Uemura M, Nojima S, Imamura R, Mubeen A, Netto GJ, Tsujikawa K, Nakamura S, Takeda K, Morii E, Nonomura N. Matsushita M, et al. Among authors: hase h. Int J Cancer. 2022 Aug 15;151(4):623-636. doi: 10.1002/ijc.34028. Epub 2022 Apr 26. Int J Cancer. 2022. PMID: 35403732
The Authors Reply.
Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura Y, Nakanishi T. Kuragano T, et al. Among authors: hase h. Kidney Int. 2015 Jul;88(1):197-8. doi: 10.1038/ki.2015.129. Kidney Int. 2015. PMID: 26126097 Free article. No abstract available.
Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study.
Narita I, Hayashi T, Maruyama S, Masaki T, Nangaku M, Nishino T, Sato H, Sofue T, Wada T, Imai E, Iwasaki M, Mizuno K, Hase H, Kamouchi M, Yamamoto H, Kagimura T, Tanabe K, Kato H, Wada T, Usui T, Akizawa T, Hirakata H, Tsubakihara Y. Narita I, et al. Among authors: hase h. PLoS One. 2022 Nov 29;17(11):e0277921. doi: 10.1371/journal.pone.0277921. eCollection 2022. PLoS One. 2022. PMID: 36445882 Free PMC article.
211 results